Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Dermatology

Can PG Subtypes Change Both Treatment and Prognosis?

At a Glance

Pyoderma gangrenosum subtype provides clues about how skin sores behave and which associated diseases to screen for, but it does not determine treatment or prognosis alone. Care depends on severity, spread, active conditions, wound factors, and complications.

Knowing your specific pyoderma gangrenosum (PG) subtype can provide your care team with important clues about how your skin lesions might look and which underlying health conditions you might need to be screened for [1]. However, the subtype label is just one factor in treatment planning, not the sole determinant of your treatment options or your prognosis (the expected course and outlook of the disease) [2][3]. Instead, your doctors will tailor your treatment based on the severity of your skin lesions, how rapidly they are spreading, and whether you have other active diseases [4][5].

It is important to know that PG is not contagious. Because PG can mimic other conditions, your doctor may need to perform biopsies and cultures to rule out actual infections, vasculitis, or vascular ulcers before confirming the diagnosis [6].

The Four Main Clinical Patterns of Pyoderma Gangrenosum

Doctors generally describe four common clinical patterns of PG based on how the lesions appear and behave. These categories can sometimes overlap.

Subtype Pattern Typical Appearance & Location Commonly Associated Conditions Usual Progression
Classic Ulcerative Deep, painful ulcer with undermined (overhanging) purple/red edges; usually on lower legs [6][7] Inflammatory bowel disease (IBD), inflammatory arthritis [6] Rapid [6]
Bullous Painful, fluid-filled blisters that rapidly ulcerate [8] Hematologic (blood) disorders, such as leukemia [8][9] Rapid [10]
Pustular Painful, sterile pustules (pus-filled bumps caused by inflammation, not infection) [11][12] Inflammatory bowel disease (IBD) [11] Variable
Vegetative Superficial ulcers with thick, raised edges; usually on the trunk [13] Rarely associated with underlying systemic diseases [13] Slower [13]
  • Classic Ulcerative: This is the most common and destructive form of the disease. When classic ulcers heal, they often leave behind characteristic cribriform scars, which have a wrinkled, paper-like or crisscrossed appearance [7][14].
  • Bullous: Because of its strong link to blood conditions, a bullous PG diagnosis should prompt an individualized evaluation of your blood counts [8].
  • Pustular: The pustules in this subtype are “sterile” meaning the primary inflammation is not caused by an infection [11]. However, secondary infections can still occur in open wounds.
  • Vegetative (Superficial Granulomatous): These lesions are generally less aggressive than the classic ulcerative form, though they still require medical management [13].

Do Subtypes Guarantee an Associated Disease?

While certain PG subtypes are traditionally linked to specific conditions, these are clues, not absolute rules. Across all patients with pyoderma gangrenosum, pooled estimates show that over half (around 57%) have an associated systemic disease (a condition affecting the body beyond the skin), such as inflammatory bowel disease, arthritis, or a blood disorder [1].

  • A bullous subtype raises the suspicion for a blood disorder and influences screening urgency, but it does not mean you definitively have leukemia [9].
  • Classic or pustular forms are often seen with IBD, but many patients with these subtypes have no bowel disease at all [6][11].

Because these links are not guaranteed and can emerge over time, your care team will evaluate your overall health and symptoms rather than relying entirely on the name of your skin subtype [1].

How Subtype Affects Treatment and Prognosis

Your PG subtype influences the urgency of your care and what associated diseases you are screened for, but no universally accepted subtype-specific treatment algorithm exists [2][3]. Instead, treatment choices are driven by:

  • Disease Severity: Early, mild, or localized disease (often seen in the vegetative subtype) might be managed with prescription topical anti-inflammatory treatments like corticosteroids or tacrolimus [13][4]. More aggressive or widespread disease usually requires systemic medications—like oral corticosteroids, cyclosporine, or biologics (advanced immune-targeting medications)—to calm the immune system [5][15].
  • Associated Conditions: If you have active IBD alongside your PG, your doctor might prescribe biologic medications to treat both conditions simultaneously [4][16]. Treating an underlying blood disorder may improve the skin lesions, though direct treatment for the skin is often still needed [10].
  • Wound Care and Pathergy: All types of PG can worsen with trauma, a phenomenon known as pathergy [4][17]. While routine or aggressive surgical debridement (removing dead tissue) can trigger pathergy and worsen the wound, carefully planned procedures may still be necessary if a true infection or complication occurs [17]. Never attempt to debride the wound yourself; always coordinate care with a PG-experienced dermatologist and wound-care team.

Prognosis and Healing

Prognosis is highly individual. Large, deep classic ulcers can take weeks, months, or even years to fully heal and may leave significant scarring [14][7]. Healing time is influenced by multiple factors, including pain, mobility, wound size and depth, vascular health, nutrition, and comorbidities, rather than just the subtype [4]. Furthermore, PG is a relapsing condition; one registry study estimated that up to 41% of patients experience a recurrence within 5 years after healing [18].

When to Seek Urgent Medical Care

Because PG can mimic infections and open ulcers are at risk for secondary bacterial infections, seek prompt medical assessment if you experience:

  • Fever or feeling generally unwell
  • Rapidly worsening pain, warmth, or redness around the ulcer
  • Foul-smelling or increasing drainage from the wound

Common questions in this guide

Do pyoderma gangrenosum subtypes determine which treatment I need?
No. There is no universally accepted treatment plan for each subtype; doctors consider how severe and fast-spreading the sores are, whether another disease is active, and your wound-care needs. Mild, localized disease may be treated with topical corticosteroids or tacrolimus, while widespread disease may need oral corticosteroids, cyclosporine, or biologic medicines.
What does a bullous PG diagnosis mean for my health?
Bullous PG causes painful blisters that can break down into ulcers and is more often associated with blood disorders. Your clinician may check blood counts and other health information, but this subtype does not prove that you have leukemia.
Can my PG subtype predict how long healing will take?
The subtype offers clues, but it cannot predict an individual outcome. Vegetative PG is often slower and less aggressive, while deep classic ulcers may take weeks, months, or years to heal and can scar; wound size and depth, pain, mobility, circulation, nutrition, other illnesses, and treatment response also matter.
What other conditions should be checked when I have PG?
Doctors may evaluate for inflammatory bowel disease, inflammatory arthritis, or a blood disorder, especially when the skin pattern suggests one of these links. These associations are not certain, and a person can develop an associated condition later, so screening is based on symptoms, health history, and follow-up.
Can wound treatment make pyoderma gangrenosum worse?
Yes. Injury to the skin can trigger pathergy, meaning an ulcer may worsen after trauma, and aggressive debridement can make PG worse. Do not remove tissue yourself; dressing changes and any procedure should be planned with a dermatologist and wound-care team familiar with PG.
When should I seek urgent care for a PG wound?
Seek prompt medical assessment for fever, feeling very unwell, rapidly worsening pain, increasing warmth or redness around the ulcer, or foul-smelling or increasing drainage. These signs can indicate a secondary infection or another complication, and PG can resemble infection, so evaluation is important.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my clinical evaluation and biopsies, what subtype or pattern of PG do you suspect I have?
  2. 2.Given my pattern and symptoms, what targeted screenings should we perform for associated systemic diseases (like IBD or blood disorders)?
  3. 3.How does the size, location, and rapid spread of my ulcers influence whether we use local therapies, systemic medications, or biologics?
  4. 4.Can you refer me to a PG-experienced wound care specialist to coordinate dressing changes without triggering pathergy?
  5. 5.What are the signs of improvement we should look for, and when should I contact you if things are worsening?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis.

    Kridin K, Cohen AD, Amber KT

    American journal of clinical dermatology 2018; (19(4)):479-487 doi:10.1007/s40257-018-0356-7.

    PMID: 29721816
  2. 2

    Pyoderma gangrenosum and underlying diseases in Japanese patients: A regional long-term study.

    Inoue S, Furuta JI, Fujisawa Y, et al.

    The Journal of dermatology 2017; (44(11)):1281-1284 doi:10.1111/1346-8138.13937.

    PMID: 28635156
  3. 3

    Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review.

    Sawka E, Zhou A, Latour E, et al.

    Clinical rheumatology 2021; (40(10)):3963-3969 doi:10.1007/s10067-021-05768-7.

    PMID: 34002351
  4. 4

    Treatment options for pyoderma gangrenosum.

    Quist SR, Kraas L

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2017; (15(1)):34-40 doi:10.1111/ddg.13173.

    PMID: 28140549
  5. 5

    Pyoderma gangrenosum: Classic and emerging therapies.

    Soto Vilches F, Vera-Kellet C

    Medicina clinica 2017; (149(6)):256-260 doi:10.1016/j.medcli.2017.04.013.

    PMID: 28629662
  6. 6

    Pyoderma gangrenosum - a guide to diagnosis and management .

    George C, Deroide F, Rustin M

    Clinical medicine (London, England) 2019; (19(3)):224-228 doi:10.7861/clinmedicine.19-3-224.

    PMID: 31092515
  7. 7

    Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts.

    Maverakis E, Ma C, Shinkai K, et al.

    JAMA dermatology 2018; (154(4)):461-466 doi:10.1001/jamadermatol.2017.5980.

    PMID: 29450466
  8. 8

    Bullous Pyoderma Gangrenosum With Subungual Involvement Associated With Ulcerative Colitis.

    Aktaş Karabay E, Aksu Cerman A, Kıvanc Altunay İ, Yalçın Ö

    The American Journal of dermatopathology 2017; (39(6)):476-478 doi:10.1097/DAD.0000000000000801.

    PMID: 27893467
  9. 9

    Bullous pyoderma gangrenosum as a predictor of hematological malignancies.

    Vacas AS, Bollea-Garlatti ML, Torre AC, Galimberti RL

    Anais brasileiros de dermatologia 2018; (93(1)):133-134 doi:10.1590/abd1806-4841.20187031.

    PMID: 29641716
  10. 10

    Bullous Variant of Pyoderma Gangrenosum in a Patient with Acute Myeloid Leukemia.

    Kwon CI, Lee GW, Kim CY

    Annals of dermatology 2022; (34(3)):212-215 doi:10.5021/ad.2022.34.3.212.

    PMID: 35721340
  11. 11

    A Case of Pustular Pyoderma Gangrenosum Misdiagnosed as Acute Febrile Neutrophilic Dermatosis in a Pediatric Patient.

    Yang X, Wu Y, Jiang F, Deng D

    Clinical, cosmetic and investigational dermatology 2024; (17()):493-498 doi:10.2147/CCID.S449404.

    PMID: 38435844
  12. 12

    Decoding the Histopathology of Pustular Pyoderma Gangrenosum: A Multidisciplinary Approach to Diagnosis.

    Bavikar R, Singh D

    Cureus 2024; (16(8)):e67059 doi:10.7759/cureus.67059.

    PMID: 39286710
  13. 13

    Superficial Granulomatous Pyoderma Successfully Treated with Intravenous Immunoglobulin.

    Borg Grech S, Vella Baldacchino A, Corso R, et al.

    European journal of case reports in internal medicine 2021; (8(9)):002656 doi:10.12890/2021_002656.

    PMID: 34671571
  14. 14

    Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs.

    Nishimura M, Mizutani K, Yokota N, et al.

    Journal of clinical medicine 2022; (11(23)) doi:10.3390/jcm11236924.

    PMID: 36498498
  15. 15

    An update on adalimumab for pyoderma gangrenosum.

    Yamamoto T

    Drugs of today (Barcelona, Spain : 1998) 2021; (57(9)):535-542 doi:10.1358/dot.2021.57.9.3293619.

    PMID: 34586101
  16. 16

    Diagnosis and management of peristomal pyoderma gangrenosum: A systematic review.

    Afifi L, Sanchez IM, Wallace MM, et al.

    Journal of the American Academy of Dermatology 2018; (78(6)):1195-1204.e1 doi:10.1016/j.jaad.2017.12.049.

    PMID: 29288099
  17. 17

    The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum.

    Ashchyan HJ, Butler DC, Nelson CA, et al.

    JAMA dermatology 2018; (154(4)):409-413 doi:10.1001/jamadermatol.2017.5978.

    PMID: 29450453
  18. 18

    Recurrence after healing in pyoderma gangrenosum: a prospective registry-based cohort study.

    Gillespie J, Roland-McGowan J, Downey K, et al.

    EClinicalMedicine 2026; (98()):104086 doi:10.1016/j.eclinm.2026.104086.

    PMID: 42495104

This page is for informational purposes only and does not constitute medical advice. A dermatologist and wound-care team should interpret your lesions, evaluate associated conditions, and guide treatment and prognosis.

Get notified when new evidence is published on Pyoderma gangrenosum.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.